Chemicals

Amyris to acquire Oobli, adding fermentation-derived sweet proteins

The biomanufacturing company expects to close the deal in the coming weeks, combining its manufacturing scale with Oobli’s protein fermentation platform.

Erik LindqvistNovember 16, 20265 min read0 views
Conceptual illustration of stainless-steel fermentation tanks linked by abstract molecular forms to laboratory glassware and pale protein powder.

Amyris, Inc. has announced plans to acquire Oobli Inc., a Davis, California-based developer of fermentation-derived sweet proteins for food and beverage manufacturers seeking to reduce sugar while retaining sweetness. Amyris, based in Emeryville, California, describes itself as a vertically integrated biomanufacturing company.

The acquisition is intended to combine Amyris’s scientific capabilities and manufacturing depth with Oobli’s expertise in protein fermentation. The announcement follows Amyris’s expansion earlier this year of manufacturing capacity at its advanced fermentation facility in Barra Bonita, Brazil. Amyris described the move as a commercial and technology expansion meant to accelerate its work in protein- and peptide-based solutions across end markets.

Complementary platforms

Kathy Fortmann, Amyris’s chief executive officer, said Oobli provides a commercial and technology platform that complements Amyris’s own. She said Oobli is poised to change how sweetness reaches the market and that Amyris intends to contribute commercial scale and resources to accelerate that effort. Fortmann also said that combining Oobli’s protein expertise with Amyris’s strain engineering, manufacturing scale and commercial capabilities could broaden its work in food and beverage, personal care, flavor and fragrance, agriculture and other areas.

Sweet protein technology

Oobli’s commercial portfolio is expected to be the first to benefit from the combined platform. The company has spent the past decade refining a fermentation process to produce sweet proteins that occur naturally in rare fruits and berries near the equator. Oobli describes its sweet proteins as the first of their kind in the sugar-reduction category. According to the company, they are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, providing sweetness without gut disruption or blood sugar spikes.

Portfolio and regulatory status

The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin. Oobli says the ingredients have FDA GRAS status and are FEMA GRAS-affirmed for use as a natural flavor. The company points to growing consumer awareness of metabolic health and sugar reduction, and says sweet proteins can give brands a new tool across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery.

Customer continuity

Ali Wing, Oobli’s chief executive officer, said the company had long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. Wing said joining Amyris would provide the scale and resources to pursue the company’s ambition of making sweet proteins a global standard in sweetness solutions. According to the announcement, all existing customer commitments and brand partnerships will continue to be honored uninterrupted as Oobli’s portfolio expands within Amyris.

The acquisition is expected to close in the coming weeks.